Xenon Pharmaceuticals Inc

NASDAQ:XENE   3:59:52 PM EDT
30.63
-0.10 (-0.32%)
Products, Regulatory

Xenon Pharmaceuticals Inc Announces Positive Topline Results From Phase 2B ‘X-TOLE’ Clinical Trial of XEN1101

Published: 10/04/2021 12:05 GMT
Xenon Pharmaceuticals Inc (XENE) - Xenon Pharmaceuticals Announces Positive Topline Results From Phase 2b 'x-tole' Clinical Trial of Xen1101 for Treatment of Focal Epilepsy.
Xenon Pharmaceuticals Inc - Xen1101 Was Generally Well-tolerated in This Study With Adverse Events (aes) Consistent With Other Asms.
Xenon Pharmaceuticals Inc - Monotonic Dose Response Relationship Between Xen1101 Active Dose Groups Compared to Placebo Was Statistically Significant.
Xenon Pharmaceuticals Inc - Median Percent Reduction in Monthly Focal Seizure Frequency Was 52.8% in Xen1101 25 Mg Group.
Xenon Pharmaceuticals Inc - Xen1101 Demonstrated Statistically Significant Reduction in Monthly Focal Seizure Frequency in Pairwise Versus Placebo.